Company Description
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States.
The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.
It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma.
It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jul 17, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 43 |
| CEO | Jason Lettmann |
Contact Details
Address: 323 Allerton Avenue South San Francisco, California 94080 United States | |
| Phone | 650 466 7125 |
| Website | alxoncology.com |
Stock Details
| Ticker Symbol | ALXO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 1810182 |
| CUSIP Number | 00166B105 |
| ISIN Number | US00166B1052 |
| Employer ID | 85-0642577 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jason W. Lettmann | Chief Executive Officer and Director |
| Shelly Pinto CPA | Senior Vice President of Finance and Chief Accounting Officer |
| Harish Shantharam C.F.A. | Chief Financial Officer |
| Dr. Athanasios Tsiatis M.D. | Senior Vice President of Clinical Development |
| Dr. Lin Yeong-Liang M.D., M.S. | Senior Vice President of Drug Safety and Pharmacovigilance |
| Lisa Sauer | Senior Vice President of Regulatory Affairs and Quality Assurance |
| Sue Naim | Senior Vice President of Clinical Operations |
| Venita De Almeida Ph.D. | Vice President and Head of Research Program Development |
| Dr. Barbara J. Klencke M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 9, 2026 | 10-K | Annual Report |
| Feb 27, 2026 | 8-K | Current Report |
| Feb 9, 2026 | SCHEDULE 13G | Filing |
| Feb 6, 2026 | SCHEDULE 13G | Filing |
| Feb 4, 2026 | SCHEDULE 13D/A | Filing |
| Jan 30, 2026 | 424B5 | Filing |
| Jan 30, 2026 | 8-K | Current Report |
| Jan 30, 2026 | 8-K | Current Report |
| Jan 21, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jan 21, 2026 | 8-K | Current Report |